title: [Comparison of Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab as a First-Line Treatment of Macular Oedema due to Retinal Vein Occlusion].
abstract: OBJECTIVE
  The present study investigated the treatment effect of dexamethasone implant (Ozurdex®, group 1) and anti-VEGF injection (Lucentis®, group 2) in course of macular oedema due to retinal vein occlusion in a retrospective, non-randomised case series.
  
  
  METHODS
  Group 1 comprised 60 patients (31 with CRVO and 29 with BRVO) and group 2 included 52 patients, 27 with CRVO and 25 with BRVO) and both groups were further treated in case of recurrence. Preoperative and in monthly intervals best corrected visual acuity (BCVA), central retinal thickness using SD-OCT (Spectralis, Heidelberg Engineering), intraocular pressure, biomicroscopy status and a fundus photo documentation (Optomap) were evaluated. The primary clinical endpoint was visual acuity 12 months after the first intravitreal therapy, while secondary endpoints included the central retinal thickness change and safety of therapy.
  
  
  RESULTS
  In group 1, an increase of BCVA (± standard deviation) of 8.4 (± 1.9) letters was observed in CRVO patients and a gain of 10.7 (± 3.8) letters in BRVO patients after 12 months, while in group 2, an increase of BCVA of 6.9 (± 1.9) letters (CRVO) compared to 12.5 (± 3.7) letters (BRVO) was observed after the same time span. In both groups a significant reduction in retinal thickness was achieved. An increase of intraocular pressure above 5 mmHg was observed in nearly half of the cases In group 1, but was well controlled by conservative antiglaucomatous therapy. We observed a progression of lens opacity in approximately 50 % of the cases in group 1.
  
  
  CONCLUSIONS
  The treatment with Ozurdex compared to Lucentis appears to provide a trend towards a better although not significant visual acuity increase after 12 months in CRVO patients. A similar trend favouring anti-VEGF treatment with Lucentis was seen in patients with BRVO. However, the lens status and age of the patient should be taken into account when considering a treatment with Ozurdex.
authors.affiliation: Augenklinik der Ludwig-Maximilians-Universität München.
authors.forename: W J
authors.initials: WJ
authors.lastname: Mayer
authors.affiliation: Augenklinik des Bürgerhospitals Frankfurt am Main.
authors.forename: A
authors.initials: A
authors.lastname: Hadjigoli
authors.affiliation: Augenklinik der Ludwig-Maximilians-Universität München.
authors.forename: A
authors.initials: A
authors.lastname: Wolf
authors.affiliation: Augenklinik der Ludwig-Maximilians-Universität München.
authors.forename: T
authors.initials: T
authors.lastname: Herold
authors.affiliation: Augenklinik Herzog Carl Theodor München.
authors.forename: C
authors.initials: C
authors.lastname: Haritoglou
mesh_terms: D004343:Drug Implants / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D020127:Recovery of Function / Q000187:drug effects; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D004343:Drug Implants